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Abstract
The anti-human epidermal growth factor receptor 2 (HER2) agent
trastuzumab has improved outcomes in breast cancer patients with
HER2 over-expressing tumours. However, systemic treatment for
patients with HER2-negative disease is still limited to endocrine and
cytotoxic therapies. The increasing use of the anthracyclines and
taxanes in early stage disease has reduced the available therapeutic
options for patients with relapsed disease, and choices are further
limited for patients with triple-negative tumours, who typically have a
poor prognosis. The novel agents bevacizumab and ixabepilone
were recently approved for metastatic breast cancer, and numerous
other agents are currently in clinical development that may
contribute further valuable therapeutic options.
Introduction
Metastatic breast cancer (MBC) remains incurable in most
patients; the goals of treatment are to optimize quality of life,
manage symptoms and prolong survival. A wide array of
agents is available for the treatment of MBC, including
endocrine therapies, cytotoxic chemotherapy (Table 1) and
targeted biological agents. Treatment choice is influenced by
a large number of factors [1], and careful consideration is
required to strike a balance between the benefits of treatment
and the associated side effects.
Despite the variety of agents currently available for the
treatment of MBC, median survival remains 2 to 3 years,
indicating considerable unmet need and the necessity for
improvement. This review summarizes recent data for novel
agents, either in development or recently approved for use in
MBC, that have the potential to improve treatment outcomes
for patients with human epidermal growth factor receptor 2
(HER2)-negative disease.
Endocrine therapy
Recommendations support the use of endocrine treatment as
first-line therapy in patients with hormone-sensitive MBC
[1,2]. Tamoxifen is approved for the treatment of MBC and
has long been considered the ‘gold standard’ of therapy for
hormone-sensitive disease in premenopausal or postmeno-
pausal patients. However, this agent is associated with some
serious side effects, including thromboembolic events and
uterine cancer, both occurring predominantly in women aged
50 years or older [3].
More recently developed endocrine therapies, including the
third-generation aromatase inhibitors (anastrozole, letrozole
and exemestane) and the selective oestrogen receptor down-
regulator fulvestrant, are at least as effective as tamoxifen but
have improved tolerability [4-8]. The aromatase inhibitors are
recommended as first-line therapy for postmenopausal women
with hormone receptor-positive MBC; however, tamoxifen
remains a valuable therapeutic option [1,2]. Treatment options
for premenopausal patients include tamoxifen and ovarian
function suppression (using a luteinizing hormone-releasing
hormone agonist) or a combination of both [1,2].
Fulvestrant is recommended for second-line therapy after
failure of tamoxifen and for third-line therapy after failure of
tamoxifen and aromatase inhibitors. Other third-line agents
that are used after other options have failed include
progestins, androgens or high-dose oestrogens [1,2]. The
increasing use of selective oestrogen receptor modulators
and aromatase inhibitors in the adjuvant setting may limit their
utility in the treatment of relapsed disease, and data on
rechallenging with these agents are limited.
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Chemotherapy
Cytotoxic chemotherapy is the treatment modality of choice
for patients with aggressive or symptomatic visceral disease,
a short disease-free interval since adjuvant treatment, hor-
mone receptor-negative disease, endocrine therapy-refractory
hormone receptor-positive disease, or rapidly progressive
hormone receptor-positive disease.
Anthracyclines and taxanes, used as single agents or in
combination, are the most popular cytotoxic agents for the
treatment of MBC [1]. Partly because of the increasing use of
these agents in the adjuvant setting, an issue currently facing
physicians is the choice of treatment in patients with
anthracycline-resistant or taxane-resistant disease. Agents
including capecitabine and vinorelbine have demonstrated
clinical benefit as monotherapy and combination therapy in
such patients. Gemcitabine and ixabepilone have demon-
strated clinical benefit only when used in combination with
taxanes and capecitabine, respectively [1].
Triple-negative breast cancer
The term ‘triple-negative’ breast cancer (TNBC) refers to a
subgroup of patients whose tumours do not express HER2 or
hormone receptors. Gene expression analysis has defined
five distinct subtypes of breast cancer, with predictive and
prognostic implications [9]. One of these, the basal-like
subtype, shares numerous clinical and pathological features
with the triple-negative phenotype, but - although there is
significant overlap between the two groups - they are not
synonymous [10].
Although patients with TNBC show some sensitivity to taxane
and anthracycline-based regimens, they generally are at
greater risk for early systemic recurrence and poorer survival
than are their non-TNBC counterparts [11,12]. Interestingly,
recent clinical trial data indicate that adjuvant tandem high-
dose chemotherapy may be more effective than standard-
dose therapy in improving 5-year event-free survival and
overall survival in patients with the triple-negative phenotype
[13].
Recent evidence suggests that TNBC may have increased
susceptibility to platinum-based therapies relative to other
breast cancers, and this has revived interest in their use
[14,15]. Triple-negative tumours are known to have reduced
levels of the DNA repair protein BRCA1, increasing their
sensitivity to the DNA-damaging effects of platinum com-
pounds [16]. Further information on this subject is expected
from an ongoing phase III trial (NCT00532727), which is
comparing platinum therapy (carboplatin) with taxane therapy
Table 1
Preferred chemotherapy and endocrine agents and regimens for HER2-negative metastatic breast cancer
Type of therapy Type of regimen/class of agent Agents
Cytotoxic chemotherapiesa Single agents Anthracyclines: doxorubicin (A), epirubicin (E), pegylated liposomal 
doxorubicin
Taxanes: paclitaxel (T), docetaxel (T), nab-paclitaxel
Fluoropyrimidines: capecitabine
Others: vinorelbine, gemcitabine (G) 
Combination chemotherapy Anthracycline based: CAF/FAC, FEC, AC, EC
Taxane-based: T/cisplatin, TG, T/carboplatin, T/capecitabine
Anthracycline/taxane: AT
Other: CMF
Combinations with targeted or  Bevacizumab + paclitaxel
specific anti-VEGF agents
Endocrine therapies Aromatase inhibitors Steroidal (type I): exemestane
Nonsteroidal (type II): anastrozole, letrozole
SERMs (anti-oestrogens) Tamoxifen
Toremifene
SERD Fulvestrant
Progestin Megestrol acetate
Androgen Fluoxymesterone
High-dose oestrogen Ethinylestradiol
Adapted from Beslija and coworkers [1] and the National Comprehensive Cancer Network [2]. aAdditional active agents are as follows: oral
etoposide, vinblastine, 5-fluorouracil (F) continuous infusion, ixabepilone, and ixabepilone plus capecitabine. AC, doxorubicin, cyclophosphamide;
CMF, cyclophosphamide, methotrexate, 5-fluorouracil; EC, epirubicin, cyclophosphamide; FAC/CAF, 5-fluorouracil, doxorubicin,
cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; HER2, human epidermal growth factor receptor 2; SERD, selective
oestrogen receptor downregulator; SERM, selective oestrogen receptor modulator; VEGF, vascular endothelial growth factor.(docetaxel) in patients with triple-negative MBC. The
estimated completion date of this trial, which aims to recruit
around 400 patients, is 2012.
Novel cytotoxic chemotherapy agents
Novel taxane formulations
Nanoparticle albumin-bound paclitaxel
Polyethoxylated castor oil is required to make the chemo-
therapy agent paclitaxel water soluble before administration.
Unfortunately, this excipient is also associated with hyper-
sensitivity reactions, frequently necessitating pretreatment
with steroids and ultimately compromising drug delivery to
the tumour [17]. A new formulation of nanoparticle albumin-
bound paclitaxel (nab-paclitaxel, ABI-007; Table 2) is
available as an alternative to paclitaxel, with the aim of
reducing the potential for allergic reactions and improving
penetration of the drug into the tumour. Indeed, in a phase III
study comparing nab-paclitaxel with polyethoxylated castor
oil-based paclitaxel in 454 patients with MBC, a significantly
higher response rate (RR; 33% versus 19%, respectively;
P = 0.001) and a longer time to progression (hazard ratio
[HR] = 0.75; P = 0.006) was reported with nab-paclitaxel
[18]. In addition, the incidence of grade 4 neutropenia was
significantly lower among patients receiving nab-paclitaxel
than in those receiving standard paclitaxel (P < 0.001),
although febrile neutropenia occurred at a similar incidence
with both treatments. Grade 3 sensory neuropathy was more
common in the nab-paclitaxel arm than in the standard
paclitaxel arm but, despite the fact that premedication was
not used in patients receiving nab-paclitaxel, no hyper-
sensitivity reactions occurred with this agent.
These findings have led to the approval of nab-paclitaxel in
the USA, Canada and Europe for use in patients with MBC
who are not suitable candidates for anthracyclines, after first-
line therapy has failed. Elsewhere, studies are currently
investigating combinations of nab-paclitaxel with other
agents, including the novel anti-angiogenic agents sorafenib
and bevacizumab. Preliminary data suggest that the latter
agent is active and well tolerated in combination with nab-
paclitaxel [19-21].
Larotaxel
Larotaxel is a novel semisynthetic taxane that was selected
for clinical development based on preclinical efficacy against
multidrug-resistant tumours and its ability to cross the blood-
brain barrier (Table 2). Larotaxel has subsequently shown
good clinical activity, manageable toxicity and a favourable
therapeutic index in a phase II trial conducted in 130 patients
who had received prior taxane therapy for MBC [22]. In
general, clinical outcomes in this study were better among
non-taxane-resistant patients compared with those who were
taxane resistant, with overall response rates (ORRs) of 42%
and 19%, median durations of response of 5.3 months and
5.0 months, median times to progression of 5.4 months and
1.6 months, and median survival times of 22.6 months and
9.8 months, respectively.
Epothilones
The epothilones are a novel class of microtubule-stabilizing
anticancer drugs that prevent cell division, leading to cell
cycle arrest [23]. Preclinical studies indicate that these agents
have a relatively broad spectrum of activity in paclitaxel-
resistant breast cancer models [24]. Several members of this
drug class are currently in clinical development [25]
(Table 2).
Ixabepilone
Ixabepilone, a semisynthetic derivative of epothilone B, is the
only approved therapeutic agent in this class of drug and has
shown significant clinical activity in patients with taxane-
resistant and anthracycline-resistant tumours. Combination
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Table 2
Novel cytotoxic agents under investigation or approved for metastatic breast cancer
Agent Drug class Stage of development in breast cancer
Nanoparticle albumin-bound (nab-) paclitaxel Taxane Approved
Larotaxel Taxane III
Ixabepilone Epothilone Approved
Patupilone Epothilone II
ZK-EPO Epothilone II
BMS-310705 Epothilone I
KOS-862 Epothilone Discontinued
Vinflunine Vinca alkaloid II
Eribulin Mitotic inhibitor III
Trabectedin Nucleotide excision repair inhibitor, cell cycle inhibitor IIItherapy with ixabepilone and the oral fluoropyrimidine
capecitabine significantly prolonged progression-free survival
(PFS) compared with capecitabine alone in a phase III study
of 752 patients with MBC resistant to anthracyclines and
taxanes (HR = 0.75; P = 0.0003) [26]. However, the inci-
dences of grade 3/4 fatigue (9% versus 3%) and neutropenia
(68% versus 11%) were higher in the combination arm. Also,
grade 3/4 sensory neuropathy occurred in 21% of patients
given ixabepilone plus capecitabine, but this was not
reported among patients receiving capecitabine alone. These
data have been confirmed in other clinical studies of
ixabepilone.
Another open-label, phase III trial randomized 1,221 patients
with MBC to receive either ixabepilone plus capecitabine or
capecitabine alone [27]. In both arms, 74% of patients had
previously received taxanes in the metastatic setting.
Haematological and nonhaematological toxicities were com-
parable to those in the aforementioned study, and cardio-
vascular events (1.8%) and toxic deaths (0.7%) were similar
between treatment arms. A statistically significant improve-
ment in PFS was seen in the ixabepilone arm but, like the
previous study, overall survival was not significantly different
in the combination arm.
Ixabepilone has also shown efficacy in patients with TNBC. In
a subgroup analysis of data from two studies of patients with
anthracycline-pretreated MBC, patients with triple-negative
disease receiving ixabepilone achieved similar response rates
to patients with other disease subtypes [28]. As a result of
these studies, ixabepilone is approved in the USA but not in
the European Union in combination with capecitabine for the
treatment of anthracycline- and taxane-pretreated MBC, or for
use as a monotherapy in the treatment of anthracycline-,
taxane- and capecitabine-pretreated disease.
Patupilone
Patupilone (EPO-906) is structurally similar to ixabepilone but
it has a different activity and toxicity profile, and is currently
under investigation in MBC patients with central nervous
system (CNS) metastases [29]. This dual-centre, open-label,
phase II study aims to enroll 45 patients, and has a primary
end-point of 3-month CNS PFS. Preliminary results from 17
patients, all of whom had received prior chemotherapy and
irradiation, indicate that patupilone has modest activity in this
patient group, with a 3-month PFS in the CNS of 8% [29].
Other novel cytotoxic agents
Vinflunine
The third-generation vinca alkaloid vinflunine (Table 2) has
demonstrated clinical efficacy in the treatment of MBC. In a
phase II trial, 31% of patients receiving vinflunine as second-
line therapy for anthracycline-pretreated and taxane-pre-
treated disease achieved a partial response, and median PFS
was 4.2 months [30]. Tolerability was generally considered to
be manageable by the study investigators, although 64% of
patients developed grade 3/4 neutropenia. A similar study
demonstrated clinical activity in the third-line setting [31].
Another phase II trial is planned, which will assess efficacy
and safety of vinflunine in combination with capecitabine in
patients with previously treated MBC; this study is not yet
open for recruitment.
Eribulin
Eribulin is a synthetic analogue of halichondrin B, a naturally
occurring microtubule inhibitor isolated from a marine sponge
(Table 2). Eribulin monotherapy has shown clinical activity in
phase II studies of heavily pretreated MBC patients, while
exhibiting a relatively favourable toxicity profile, with neutro-
penia, fatigue and neuropathy being the most frequently
reported grade 3/4 adverse events [32-34]. Phase III studies
are currently underway to compare the efficacy and safety of
eribulin with commonly used treatment regimens in patients
with pretreated MBC.
Trabectedin
Trabectedin is another novel agent of marine origin, which
interacts with DNA leading to transcriptional inhibition
(Table 2) [35]. A small phase II study has reported a
confirmed RR of 14% for single-agent trabectedin in 21 MBC
patients who had received one or two prior chemotherapy
regimens [36]. The most frequently occurring adverse event
was transaminitis, which was observed in most patients; 33%
of patients experienced grade 4 neutropenia. A phase III
open-label trial is ongoing to investigate trabectedin in
different subtypes of pretreated MBC, including one cohort of
patients with triple-negative disease.
Anti-angiogenic agents
For a tumour to survive and grow, it needs to develop and
maintain a network of blood vessels. Angiogenesis, the
growth of new blood vessels, is therefore regarded as a key
target for the development of new therapeutic strategies for
breast cancer, as well as many other cancer types. A number
of agents have been developed to inhibit the vascular
endothelial growth factor (VEGF) pathway, which plays a key
role in both normal and tumour angiogenesis (Table 3). To
date, the most successful strategies have been based on
direct inhibition of the VEGF ligand with a specific
monoclonal antibody, or inhibition of the VEGF receptor using
small-molecule tyrosine kinase inhibitors (TKIs).
Anti-VEGF monoclonal antibodies: bevacizumab
Bevacizumab is a humanized monoclonal antibody directed
against VEGF and, to date, is the only inhibitor of the VEGF
pathway to have received regulatory approval for use in MBC.
This approval was based on the findings of a large phase III
trial (E2100) that compared the clinical efficacy of
bevacizumab (10 mg/kg every 2 weeks) plus weekly paclitaxel
with paclitaxel alone in 722 patients with locally recurrent or
MBC who had not received prior chemotherapy [37]. Patients
receiving the combination regimen showed significant
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versus 23%; P < 0.0001) compared with those receiving
paclitaxel monotherapy. More than 90% of patients enrolled in
this trial had HER2-negative disease. These investigator-
assessed data were confirmed by an independent review
facility, validating the original observations [37].
A subsequent phase III trial, AVADO, has studied the efficacy
of bevacizumab when combined with another widely used
taxane, docetaxel [38]. This study compared two doses of
bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus docetaxel
versus placebo plus docetaxel. PFS was significantly
increased with both doses of bevacizumab plus docetaxel
(7.5 mg/kg: median 8.7 months; HR = 0.69, P = 0.0035;
15 mg/kg: median 8.8 months; HR = 0.61, P = 0.0001) com-
pared with docetaxel plus placebo (median 8.0 months), as
was RR (7.5 mg/kg: 55%; 15 mg/kg: 63%; placebo: 44%).
All patients enrolled in this trial had HER2-negative disease.
In addition to its well described efficacy profile in MBC,
bevacizumab is also well tolerated, and when it is combined
with a taxane it does not impact greatly on the known safety
profile of these agents. Previously reported adverse events of
special interest for bevacizumab include hypertension,
proteinuria, gastrointestinal perforations, wound-healing com-
plications, haemorrhage, thromboembolic events, neutro-
penia, abscesses/fistulae, congestive heart failure and
reversible posterior leukoencephalopathy syndrome. Although
some of these adverse events of special interest were seen
more frequently in the bevacizumab-containing treatment
arms of both phase III studies, they were generally manage-
able [38,39]. Of note, in AVADO gastrointestinal perfora-
tions, arterial and venous thromboembolic events, congestive
heart failure, fistula/abscess, bleeding events, proteinuria and
wound-healing complications were not more common in the
bevacizumab arms than in the placebo arm [38].
VEGF receptor tyrosine kinase inhibitors
Several small-molecule receptor TKIs are currently under
investigation for use in MBC, including sunitinib, sorafenib,
vandetanib and axitinib. These agents are multitargeted,
inhibiting numerous other receptor tyrosine kinases in
addition to the VEGF receptors (Table 3).
Preliminary data indicate that sunitinib, an oral multitargeted
TKI with both anti-angiogenic and antitumour activities, has
some activity in patients with pretreated MBC [40]. A small
phase II trial of 23 patients receiving sunitinib reported a
partial response rate of 17%, but haematologic toxicity was
high and dose modification was required in approximately
50% of patients [40]. No data are currently available for
sunitinib in combination with chemotherapy in MBC, but four
phase II studies are underway, though two have been
suspended following futility analyses.
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Table 3
Specific or targeted anti-angiogenic agents under investigation or approved for metastatic breast cancer
Agent Class of agent Target Stage of development in breast cancer
Bevacizumab Monoclonal antibody VEGF Approved
Pazopanib TKI VEGF receptor-1, -2, -3 III
PDGFR-β
c-Kit
Sunitinib TKI VEGF receptor-1, -2, -3 III
PDGFR-β
c-Kit
FLT3
RET
CSF-1R
Axitinib TKI VEGF receptor-1, -2, -3 II
PDGFR-β
c-Kit
Sorafenib TKI VEGF receptor-2, -3 II
PDGFR-β
c-Kit
FLT3
RET
Raf
Vandetanib TKI VEGF receptor-2 II
RET
EGFR
CSF-1R, colony-stimulating factor-1 receptor; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; TKI,
tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.Another multitargeted agent, sorafenib, has also been
investigated in patients with pretreated MBC. In a phase II
trial in 56 patients, one patient (2%) receiving sorafenib
achieved a partial response and 19 patients (35%) had
stable disease [41]. Dose reductions due to skin rash, hand-
foot syndrome, hypertension and cramping of the hands and
feet were required. Further phase II studies of this agent in
combination with cytotoxic chemotherapy and endocrine
agents are underway.
Combination therapy with axitinib plus docetaxel has
demonstrated superior efficacy to docetaxel plus placebo in a
phase II trial conducted in 168 patients who had not
previously received chemotherapy for MBC [42]. The ORR
was 40% for the docetaxel plus axitinib arm and 23% for the
docetaxel plus placebo arm (P = 0.038). Grade 3/4 adverse
events that were increased with axitinib plus docetaxel versus
docetaxel plus placebo included febrile neutropenia (16%
versus 7%), fatigue (13% versus 5%), stomatitis (13% versus
2%), diarrhoea (11% versus 0%) and hypertension (5%
versus 2%). Axitinib is currently undergoing further evaluation
in patients with MBC.
Two phase II trials of vandetanib in patients with MBC have
been completed without yielding any firm evidence of
efficacy. One study, a comparison of vandetanib plus doce-
taxel with placebo plus docetaxel in 62 patients with MBC,
did not meet its primary end-point (number of progression
events) [43]. The second study investigated single-agent
vandetanib in 46 patients, but it reported no objective
responses [44]. A phase II study of this agent in combination
with the aromatase inhibitor anastrozole is currently
recruiting. Elsewhere, no clinical trials have been reported
with pazopanib in MBC, but a phase II study is underway to
assess the activity of this agent as a monotherapy. Ultimately,
given the success of the anti-angiogenic approach using
bevacizumab in patients with HER2-negative disease, further
investigation of these small-molecule TKIs in this patient
group is warranted.
Targeting the epidermal growth factor
receptor family
The epidermal growth factor receptors (EGFRs) are a family
of transmembrane proteins that trigger intracellular pathways
responsible for cell growth via tyrosine kinase activation. Four
receptors have been identified and given the acronym HER
(human epidermal growth factor receptor): EGFR/HER1,
HER2/neu, HER3 and HER4.
The development of trastuzumab, an antibody against HER2
(Table 4), significantly improved the outcome for patients with
HER2 over-expressing breast cancer, and is now a widely
recognized treatment option in this patient group. Indeed,
combination therapy with trastuzumab plus chemotherapy is
the current standard first-line treatment for HER2-positive
MBC, and breast cancer patients are routinely tested to
determine their HER2 status. A recent retrospective analysis
revealed that some patients with HER2-negative disease may
also benefit from the addition of trastuzumab to their chemo-
therapy regimen [45]. Response to trastuzumab in these
patients may be linked to polysomy of chromosome 17 [46].
EGFR over-expression has been noted in some breast
tumours, most frequently in the basal subtype [47], and has
been linked to poor prognosis [48]. However, EGFR
expression is not a reliable marker of response to EGFR
inhibitors, and EGFR status is not yet routinely tested in
breast cancer [49].
Lapatinib is a dual inhibitor of EGFR and HER2 (Table 4) and
is approved in combination with capecitabine for second-line
or later-line treatment (after anthracyclines and taxanes) of
patients with HER2-positive disease who have received prior
trastuzumab therapy. However, lapatinib appears to offer
little, if any, benefit to patients with HER2-negative disease. In
a large phase III study investigating the combination of
lapatinib and paclitaxel versus placebo and paclitaxel, the
lapatinib combination failed to show any benefit over
paclitaxel alone in patients with HER2-negative disease [50].
The EGFR inhibitor erlotinib (Table 4) is an effective
treatment for patients with pancreatic or non-small-cell lung
cancer; however, its efficacy in MBC remains unclear. In a
phase II trial, single-agent erlotinib had minimal activity in
heavily pretreated patients with MBC, with only one partial
response and three cases of stable disease (≥12 weeks)
among 69 treated patients [51]. In another phase II study of
37 patients receiving erlotinib with the anti-angiogenic agent
bevacizumab, one partial response was reported and four
patients achieved stable disease (>9 months) [52]. Another
study suggests that greater clinical success may be achieved
by combining erlotinib with gemcitabine, yielding a 14%
response rate [53]. Further phase II trials with erlotinib in
MBC are ongoing.
In a phase II study, patients with triple-negative MBC
received combination therapy with the EGFR inhibitor
cetuximab (Table 4) and carboplatin [54]. In arm 1 of the trial,
patients were treated with single-agent cetuximab until
disease progression, and then carboplatin was added;
patients in arm 2 received combination therapy throughout.
The ORR was low in both arms but favoured combination
therapy (arm 1: 6%; arm 2: 18%). Adverse events occurred
more frequently in the combination arm, most commonly rash,
fatigue and nausea. Phase II studies of cetuximab in
combination with other agents in MBC are ongoing.
A phase II study of single-agent gefitinib (Table 4) in 58
patients with taxane-pretreated and anthracycline-pretreated
MBC produced an ORR of only 1.7% [55]. Gefitinib was well
tolerated, but it was not efficacious as a single agent in this
setting. Two randomized phase II trials of gefitinib in
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results [56,57]: one showed no efficacy benefit, but
increased toxicity versus docetaxel alone, and the other was
closed early due to treatment-related toxicity. Development of
gefitinib in breast cancer has been discontinued.
Considerable interest has been expressed in modulation of
resistance to endocrine therapies by concomitant inhibition of
the EGFR pathway [58]. Preclinical studies have shown that
combining fulvestrant with gefitinib may result in greater
antitumour activity than fulvestrant alone in patients with
hormone receptor-positive advanced breast cancer [59,60]. It
is hoped that ongoing trials will determine whether conco-
mitant targeting of the EGFR pathway will delay the onset of
resistance to fulvestrant in this setting [61]. Another ongoing
phase III trial is examining the effect of letrozole with or
without lapatinib in patients with hormone receptor-positive
MBC.
Overall, the success of EGFR inhibitors in MBC has been
mixed. Although trastuzumab remains an agent of choice for
patients with HER2-positive disease, there remains a lack of
treatment options for patients with HER2-negative disease,
and new therapeutic options for this patient population are
required.
Mammalian target of rapamycin inhibitors
Mammalian target of rapamycin (mTOR) is a serine/threonine-
protein kinase that is vital to the regulatory mechanisms of
cell growth. mTOR inhibitors that have been, or are being,
studied in breast cancer include sirolimus, temsirolimus,
everolimus and deforolimus (Table 5).
The most promising data in this class have been reported
from studies of temsirolimus; data with other agents remain
limited. An ORR of 9.2% was reported in a phase II study of
106 patients with MBC receiving temsirolimus [62], whereas
in another phase II study there was an improvement in PFS in
postmenopausal women with locally advanced or MBC
receiving temsirolimus combined with letrozole [63]. In a
preliminary analysis of this study, median PFS in patients
receiving temsirolimus plus letrozole was 13.2 months, as
compared with 11.6 months in patients who received
letrozole alone. A phase III randomized, double-blind study
that planned to evaluate this combination further has been
discontinued.
A number of phase I and II studies are planned or ongoing
investigating everolimus in combination with chemotherapy,
endocrine agents, or erlotinib [64]. Although further clinical
study of these agents is required, the downstream location of
mTOR in relation to activated receptor tyrosine kinases, plus
the relatively mild toxicity profile of these agents, makes them
attractive clinical candidates for the treatment of patients with
MBC.
Targeting the Ras/Raf/MEK/ERK pathway
The Ras/Raf/mitogen-activated protein kinase kinase (MEK)/
extracellular signal-regulated kinase (ERK) signalling cascade
conveys mitogenic input to the cell nucleus through
sequential phosphorylation, controlling growth regulatory
functions [65]. Although Ras mutations are infrequent in
breast cancers, this signalling pathway is known to play a role
in endocrine therapy resistance [66]. Preclinical studies
combining endocrine agents with farnesyl transferase
inhibitors, which target this pathway, have reported
synergistic effects [66,67]. Therefore, drugs that inhibit the
Ras/Raf/MEK/ERK pathway may have important clinical
ramifications for breast cancer therapy [65]. A phase II trial of
two doses of the farnesyl transferase inhibitor tipifarnib
(Table 5) in patients with MBC reported response rates at
6 months of 10% and 14%, and stable disease in 15% and
9% of patients [68]. Further studies combining tipifarnib with
chemotherapy and endocrine agents are ongoing.
Poly-ADP ribose polymerase inhibitors
Poly-ADP ribose polymerase (PARP) is a nuclear enzyme that
is involved in repairing DNA damage, and it is activated when
damage of the type caused by chemotherapy and/or radio-
therapy occurs [69]. Targeting PARP may prevent tumour
cells from repairing DNA, a mechanism by which they
develop drug resistance. Indeed, PARP inhibitors may make
tumour cells more sensitive to cancer therapies [70-72]. As
PARP inhibition appears to be particularly effective against
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Table 4
Agents targeting the EGFR family under investigation or approved for metastatic breast cancer
Agent Class of agent Target Stage of development in breast cancer
Trastuzumab Monoclonal antibody HER2 Approved
Lapatinib TKI EGFR, HER2 Approved
Erlotinib TKI EGFR II
Cetuximab Monoclonal antibody EGFR II
Gefitinib TKI EGFR Discontinued
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor.BRCA1-deficient or BRCA2-deficient cells, PARP inhibitors
may be particularly useful for the treatment of hereditary
cancer with BRCA mutations [73,74]. Several PARP
inhibitors are currently being investigated in phase II trials in
patients with MBC, including KU-59436, BSI-201 and AG-
14699 (Table 5). Of note, BSI-201 is currently undergoing
evaluation in a multicentre, open-label, randomized phase II
trial in 120 patients with triple-negative MBC. Patients
receive gemcitabine plus carboplatin, either alone or in
combination with BSI-201; intriguing data were presented at
ASCO 2009 (O’Shaughnessy et al., unpublished data) with
final analysis expected in 2010.
Conclusions
Although there are many agents available for the treatment of
MBC, long-term responses are infrequent and prognosis
remains poor. Increasing use of anthracyclines and taxanes
for early breast cancer may have reduced the usefulness of
these highly active agents in the metastatic setting. Patients
with HER2-negative tumours are unlikely to benefit from
therapy with trastuzumab or lapatinib, and treatment options
are more limited for patients with triple-negative tumours.
Further study of platinum therapy and the epothilone
ixabepilone in these patients is required to determine their
value in this setting.
Phase III clinical data suggest that bevacizumab may be a
valuable treatment option for patients with HER2-negative
MBC. Given the success of this anti-angiogenic approach,
further investigation of VEGF receptor TKIs in this patient
group is warranted.
In conclusion, several agents have shown promising results in
clinical trials of patients with HER2-negative MBC. The new
biological agents offer the potential to provide additive and
synergistic therapeutic effects when used in combination with
chemotherapy, and will potentially offer improved outcomes
for MBC patients in the next few years.
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